Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
cIAP2 (cellular inhibitor of apoptosis protein 2), also known as HIAP1 or BIRC3, is a member of the inhibitor of apoptosis protein (IAP) family. It functions as a potent suppressor of apoptotic cell death and plays critical roles in regulating immune responses, inflammation, and cell survival. It directly inhibits pro-apoptotic caspases such as caspase-3 to prevent apoptosis and regulates cell survival by targeting pro-apoptotic proteins for ubiquitin-mediated degradation via its E3 ligase activity. cIAP2 expression is highly inducible by NFκB following various triggers such as cytokines or pathogen-associated molecular patterns. Because cIAPs regulate key checkpoints between life/death decisions in cells—especially under stress or inflammatory conditions—they are considered potential therapeutic targets in cancer, autoimmunity/inflammation and infectious diseases.
Promoting cancer cell death through reactivation of apoptotic pathways by inhibiting cIAP1/cIAP2.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Inhibitor of Apoptosis Protein cIAP2 (cIAP2).